Michael Stefanidakis, et al. Efficient in vivo editing of CEP290 IVS26 by EDIT-101 as a novel therapeutic for the treatment of Leber Congenital Amaurosis 10. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, April 29 – May 3, 2018.

Apr

22

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Feb

28

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Feb

21

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events